Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 216,033 | 221,038 | 162,143 | 181,496 | 208,976 |
| Cost of Goods | 54,823 | 50,070 | 35,170 | 42,120 | 47,319 |
| Gross Profit | 161,210 | 170,968 | 126,973 | 139,376 | 161,657 |
| Operating Expenses | 73,754 | 76,580 | 73,341 | 64,987 | 78,684 |
| Operating Income | 88,279 | 94,458 | 53,802 | 74,509 | 83,292 |
| Interest Expense | 4,505 | 4,494 | 4,543 | 4,570 | 7,514 |
| Other Income | 17,986 | 3,192 | 2,979 | 852 | -2,071 |
| Pre-tax Income | 101,760 | 93,156 | 52,238 | 70,791 | 73,707 |
| Income Tax | 19,923 | 18,402 | 12,623 | 13,089 | 12,073 |
| Net Income Continuous | 81,837 | 74,754 | 39,615 | 57,702 | 61,634 |
| Net Income | $81,837 | $74,754 | $39,615 | $57,702 | $61,634 |
| EPS Basic Total Ops | 0.62 | 0.57 | 0.29 | 0.43 | 0.45 |
| EPS Basic Continuous Ops | 0.62 | 0.57 | 0.29 | 0.42 | 0.45 |
| EPS Diluted Total Ops | 0.61 | 0.56 | 0.29 | 0.41 | 0.44 |
| EPS Diluted Continuous Ops | 0.61 | 0.56 | 0.29 | 0.41 | 0.44 |
| EBITDA(a) | $111,693 | $115,478 | $75,177 | $83,576 | $116,605 |